津巴布韦将从2025年开始为高风险群体试行一种新的每年预防艾滋病毒的药物。 Zimbabwe will pilot a new yearly HIV prevention drug for high-risk groups starting in 2025.

据美国驻哈拉雷大使馆称,津巴布韦被选为推出Lenacapavir的十个国家之一,这是一种新的艾滋病毒预防药物,每年只需要注射两针。 Zimbabwe has been selected as one of ten countries to roll out lenacapavir, a new HIV prevention drug requiring only two injections per year, according to the U.S. Embassy in Harare. 该药物在Gilead Science公司开发并得到全球基金和PEPFAR的支持,在试验中显示出超过99%的功效,旨在改善遵守和获得药物的机会,特别是对孕妇和哺乳妇女而言。 Developed by Gilead Sciences and supported by the Global Fund and PEPFAR, the drug showed over 99% effectiveness in trials and aims to improve adherence and access, especially for pregnant and breastfeeding women. 推出工作定于2025年开始,将利用现有的艾滋病毒服务向农村和难以接触到的人口提供服务。 The rollout, set to begin in 2025, will leverage existing HIV services to reach rural and hard-to-reach populations. 津巴布韦有近130万艾滋病毒携带者,因此,津巴布韦努力减少新感染病例,这符合到2030年将艾滋病作为公共卫生威胁加以消除的全球目标。 With nearly 1.3 million people living with HIV, Zimbabwe’s efforts to reduce new infections align with global goals to end AIDS as a public health threat by 2030.